Global Blood Therapeutics Inc. (GBT)

Name: Global Blood Therapeutics Inc. (GBT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Global Blood Therapeutics Inc. (GBT)

Stock Card

$68.49

$0.00 (0.00%)

As on 05-Oct-2022 09:30EDT

Market cap

$4,621 Mln

Revenue (TTM)

$235 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Global Blood Therapeutics (GBT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 68.49 High: 68.49

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-322 Mln
ROE

-1.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-16.5
Debt to Equity

4.9
Book Value

$--
EPS

$-5
Face value

--
Shares outstanding

67,476,200

9 Years Aggregate

CFO

$-1,024.92 Mln

EBITDA

$-1,220.39 Mln

Net Profit

$-1,276.38 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Global Blood Therapeutics (GBT)	134.0	1.0	108.8	162.2	12.5	16.2	--
BSE Sensex^*	-10.1	-3.6	2.5	-5.7	4.9	5.5	10.1
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 05-Oct-2022 | *As on 07-Sep-2026 | #As on 26-Oct-2023

Company	2021	2020	2019	2018	2017	2016
Global Blood Therapeutics (GBT)	-32.4	-45.5	93.6	4.3	172.3	-55.3
S&P Small-Cap 600	25.3	9.6	20.9	-9.7	11.7	24.7
BSE Sensex	22.0	15.8	14.4	5.9	27.9	1.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Global Blood Therapeutics (GBT)	68.5	4,621.4	234.9	-322.5	-126.6	-204.9	--	39.0
Change Healthcare (CHNG)	27.5	9,025.2	3,497.4	-77.0	4.3	-2.4	--	2.7
Hanger (HNGR)	18.7	732.4	1,175.5	37.3	5.8	31.7	19.7	5.8

Shareholding Pattern

View Details

About Global Blood Therapeutics (GBT)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral,... once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Read more

Pres, CEO & Director

Dr. Ted W. Love M.D.
Pres, CEO & Director

Dr. Ted W. Love M.D.
Headquarters

South San Francisco, CA
Website

https://www.gbt.com

FAQs for Global Blood Therapeutics (GBT)

What is the current share price of Global Blood Therapeutics Inc (GBT) Today?

The share price of Global Blood Therapeutics Inc (GBT) is $68.49 (NASDAQ) as of 05-Oct-2022 09:30 EDT. Global Blood Therapeutics Inc (GBT) has given a return of 12.53% in the last 3 years.

What is the current PB & PE ratio of Global Blood Therapeutics Inc (GBT)?

Since, TTM earnings of Global Blood Therapeutics Inc (GBT) is negative, P/E ratio is not available.
The P/B ratio of Global Blood Therapeutics Inc (GBT) is 39.05 times as on 05-Oct-2022, a 697 premium to its peers’ median range of 4.90 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	-6.08	9.39
2020	-10.67	6.35
2019	-17.28	7.97
2018	-12.02	3.65
2017	-14.12	5.18

What is the 52 Week High and Low of Global Blood Therapeutics Inc (GBT)?

The 52-week high and low of Global Blood Therapeutics Inc (GBT) are Rs -- and Rs -- as of 07-Sep-2026.

What is the market cap of Global Blood Therapeutics Inc (GBT)?

Global Blood Therapeutics Inc (GBT) has a market capitalisation of $ 4,621 Mln as on 05-Oct-2022. As per SEBI classification, it is a Small Cap company.

Should I invest in Global Blood Therapeutics Inc (GBT)?

Before investing in Global Blood Therapeutics Inc (GBT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.